Tislelizumab

Tislelizumab_PB-1_7BXA.png

Tislelizumab is a monoclonal antibody used in the treatment of various types of cancer. It is specifically designed to target and inhibit the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system.

Mechanism of Action

Tislelizumab works by binding to the PD-1 receptor on T cells, a type of white blood cell that plays a crucial role in the body's immune response. By inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2, tislelizumab enhances the ability of the immune system to detect and destroy cancer cells.

Indications

Tislelizumab is indicated for the treatment of several types of cancer, including:

• Non-small cell lung cancer (NSCLC)
• Hodgkin lymphoma
• Urothelial carcinoma

Clinical Trials

Tislelizumab has undergone multiple clinical trials to evaluate its efficacy and safety. These trials have demonstrated promising results, leading to its approval in various regions for the treatment of specific cancers.

Side Effects

Common side effects of tislelizumab include:

• Fatigue
• Nausea
• Diarrhea
• Rash
• Pruritus

Serious side effects may include:

• Immune-related adverse events such as pneumonitis, hepatitis, and colitis.

Regulatory Status

Tislelizumab has been approved for use in several countries, including China and is undergoing regulatory review in other regions.

Research and Development

Tislelizumab is being developed by BeiGene, a global biotechnology company. Ongoing research is exploring its potential in combination with other therapies and in additional cancer types.

See Also

• Monoclonal antibody therapy
• Immunotherapy
• Cancer treatment

External Links

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian